Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?
Ortner
M A
MA
Department of Gastroenterology/Hepatology, Humboldt University, Medical Faculty Charité, CCM, Schumannstrasse 20-21, D 10117 Berlin, Germany. Marianne.Ortner@charite.de
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D001471:Barrett Esophagus / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D002471:Cell Transformation, Neoplastic; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D016629:Esophagectomy; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010778:Photochemotherapy; D011159:Population Surveillance; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D011237:Predictive Value of Tests; D013057:Spectrum Analysis / Q000379:methods
D004791:Enzyme Inhibitors